Shilpa Medicare's Joint Venture Oncosol, along with its partner Shorla Oncology, on Wednesday announced that the US FDA has approved IMKELDI (imatinib oral solution). IMKELDI is the first oral liquid form of imatinib used to treat certain forms of leukemia and other cancers.

Shilpa Medicare’s joint venture Oncosol, with Shorla Oncology, has gained US FDA approval for IMKELDI, an imatinib oral solution. IMKELDI is the first liquid form of imatinib, and it will be approved for use in specific cases of cancers. Oral liquid formulation is the advanced drug form of imatinib for precise dosing.